Abstract: Multi-stage acoustophoretic devices for continuously separating a second fluid or a particulate from a host fluid are disclosed. Methods of operating the multi-stage acoustophoretic devices are also disclosed. The systems may include multiple acoustophoretic devices fluidly connected to one another in series, each acoustophoretic device comprising a flow chamber, an ultrasonic transducer capable of creating a multi-dimensional acoustic standing wave, and a reflector. The systems can further include pumps and flowmeters.

Abstract: Provided herein, among other things, is an automatable procedure that employs in vitro directed evolution to create DNA sequences that encode a ligand-responsive ribozyme and which, when transcribed, can control expression of genes they are coupled to. The method also allows creation of functional RNA sequences that bind target molecules, without requiring any modification or immobilization of the target.

Abstract: This document provides methods and materials involved in cloning functional TCRs from single T cells. For example, methods and materials for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, kits for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, methods for making such kits, collections of nucleic acid primers designed to amplify the entire coding sequence of both variable regions for each expressed V segment for functional ?? or ?? TCRs of a particular mammalian species, methods for using such collections of nucleic acid primers to clone functional TCRs from single T cells, and kits containing such collections of nucleic acid primers to clone functional TCRs from single T cells are provided.

Abstract: Compositions and methods for performing a template-switching reaction are provided that may include reducing or eliminating concatemerization of the template-switching oligonucleotide (TSO). In some embodiments, the composition may comprise: a reverse transcriptase; a TSO that includes a recognition sequence for a site-specific double strand nucleic acid cleaving enzyme, wherein the TSO has at its 3? end at least one nucleotide capable of hybridizing to at least one or more non-templated nucleotides added to a templated cDNA strand by the reverse transcriptase; and a site-specific double strand nucleic acid cleaving enzyme that cleaves the TSO at the recognition sequence.

Abstract: Provided are a new precursor miRNA and the applications in tumor therapy thereof. The precursor miRNA, from 5?- to 3?-end thereof, has the structure represented by formula (I). B1 is an anti-miRNA and/or siRNA to be expressed; B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C; C is a sequence with stem-loop structure; A1 and A2 are independently hydrogen or optionally a RNA sequence consisting of 4 to 5 bases. The precursor miRNA can be processed to form an anti-miRNA and/or siRNA in hosts.

Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Abstract: The present invention relates to an oligonucleotide comprising one of the following sequence: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant or a mixture thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a non-cancer condition associated with telomere dysfunction and relative pharmaceutical compositions and to relative pharmaceutical composition and method.

Abstract: Provided is a nucleic acid complex, preferably a double-stranded nucleic acid complex, having an excellent effect of suppressing the expression of a target gene. Further provided is a nucleic acid complex, that is, a double-stranded nucleic acid complex, comprising an active moiety comprising an antisense nucleic acid complementary to a transcript, for example, a transcript of a target gene, and a carrier moiety comprising a nucleic acid comprising DNA, preferably a DNA-based nucleic acid, which is complementary to the above-described nucleic acid.

Abstract: The present invention pertains to the improvement of a miRNA inhibitor (a synthesized Tough Decoy (S-TuD)). The present invention provides a miRNA inhibitory complex including RNA or an analog thereof, wherein the RNA inhibitory complex includes at least one double-stranded structure and a miRNA binding sequence, each of two strands of the miRNA binding sequence being bound to two strands of at least one end of the double-stranded structure, and the miRNA inhibitory complex further includes at least one crosslinked nucleic acid.

Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.

Abstract: The present disclosure relates to chimeric antisense nucleotides and methods for modulating protein expression levels and/or RNA stability from at least two target mRNAs in a cell simultaneously.

Abstract: The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.

Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.

Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.

Abstract: The present invention relates to a method for the treatment of fibrosis, in particular cardiac fibrosis, comprising the administration of an inhibitor of insulin-regulated aminopeptidase (IRAP). Preferable the IRAP inhibitor is chosen from the group including HFI-419, HA-08, AL-40, HFI-437, Val-Tyr-Ile-His-Pro-Phe (otherwise known as angiotensin IV or ANG IV), c[Cys-Tyr-Cys]-His-Pro-Phe, and c[Hcy-Tyr-Hcy]-His-Pro-Phe.

Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.

Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.

Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.

Abstract: The present disclosure provides methods and kits for generating recombinant bacteriophage genomes. Specifically, the present technology provides methods of integrating a heterologous nucleic acid sequence into a bacteriophage DNA genome, and isolating recombinant bacteriophages that express the heterologous nucleic acid sequence.

Abstract: Provided is a promoter suitable for the high expression of a gene of interest. A promoter consisting of a DNA selected from the group consisting of the following (a) to (d): (a) a DNA comprising the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 3; (b) a DNA consisting of a nucleotide sequence having at least 70% identity to the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 3 and having a promoter activity; (c) a DNA consisting of a nucleotide sequence wherein one or several of nucleotides are deleted, substituted or added in the nucleotide sequence represented by any one of SEQ ID NOS: 1 to 3 and having a promoter activity; and (d) a DNA which hybridizes with a DNA consisting of a nucleotide sequence complementary to the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 3 under stringent conditions and which has a promoter activity.

Abstract: An isolated and/or artificial pG1-x promoter, which is a functional variant of the carbon source regulatable pG1 promoter of Pichia pastoris identified by SEQ ID 1, which pG1-x promoter consists of or comprises at least a part of SEQ ID 1 with a length of at least 293 bp, characterized by the following promoter regions: a) at least one core regulatory region comprising the nucleotide sequences SEQ ID 2 and SEQ ID 3; and b) a non-core regulatory region, which is any region within the pG1-x promoter sequence other than the core regulatory region; wherein the pG1-x promoter comprises at least one mutation in any of the promoter regions and a sequence identity of at least 80% in SEQ ID 2 and SEQ ID 3, and a sequence identity of at least 50% in any region other than SEQ ID 2 or SEQ ID 3; and further wherein the pG1-x promoter is characterized by the same or an increased promoter strength and induction ratio as compared to the pG1 promoter, wherein the promoter strength is at least 1.

Abstract: Described is a plant transformed with one or more genes originating from the Ri plasmid of Agrobacterium rhizogenes by infection with A. rhizogenes comprising the Ri plasmid, or being progeny of such a plant, said plant or progeny comprising, in the genome thereof, 1 to 5 copies said one or more genes originating from the Ri plasmid. Further, the use of such a plant or progeny thereof as ornamental plants, the use as field crop species, for food extracts, cosmetics, perfumes or as medicinal plants is disclosed. Further disclosed are methods for the preparation of such plants. Said plants display an intermediate height and/or with a higher content of metabolites without significant reduction of flower number or flowering time delay as compared to control plants void of Agrobacterium rhizogenes sequences.

Abstract: The present invention relates to methods and hybrids for the targeted modification of a nucleic acid-target region in a plant target structure. The invention specifically relates to methods and hybrids for directly obtaining a plant or plant material which comprises an editing of a nucleic acid introduced in a targeted manner into a meristematic cell. The hybrids can be introduced in a transient and/or stable manner. The invention also relates to novel plant-optimized introduction strategies. The invention further relates to a method for carrying out an in vitro screening assay in order to first check the suitable gRNA candidates in vitro with respect to their efficiency.

Abstract: The present invention provides methods for enhancing the polyisoprenoid biosynthesis pathway. The present invention further provides isoprenoid-producing plants having an enhanced polyisoprenoid biosynthesis pathway, and methods for producing a polyisoprenoid using such an isoprenoid-producing plant. The present invention relates to methods for regulating the expression of specific protein(s) by a specific transcription factor; isoprenoid-producing plants into which has been introduced a gene encoding a specific transcription factor; and methods for producing a polyisoprenoid using such an isoprenoid-producing plant.

Abstract: A method of gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a cell, to generate a break in the FAD2 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.

Abstract: A touch panel may include: a sensing electrode part including a plurality of first sensing electrodes and a plurality of second sensing electrodes insulated from the first sensing electrodes and crossing the first sensing electrodes; an opening part in the sensing electrode part; and a dummy pattern adjacent to the sensing electrode part.

Abstract: A method of improving lipid productivity, containing the steps of: enhancing the expression of a gene encoding the following protein (A) or (B), and improving the productivity of medium-chain fatty acids or lipids containing these fatty acids as components produced in a cell of a transformant, or the total amount of all fatty acids produced in a cell of a transformant: (A) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1; and (B) a protein consisting of an amino acid sequence having 64% or more identity with the amino acid sequence of the protein (A), and having glycerol-3-phosphate dehydrogenase activity.

Abstract: The invention provides materials and methods for producing fruit of altered size, or plants that produce fruit of altered size, by altering expression of miRNA172 in the plants producing the fruit. The invention provides methods and materials for producing the plants and fruit of altered size by genetic modification (GM) and non-GM means. The invention also provides the plants and fruit of altered size. The altered size can be increased or decreased size.

Abstract: The present invention relates to a transgenic expression construct for plants, comprising an anti-apoptotic gene of the BAG family of plant genes and a promoter overexpressing said gene in a plant or part thereof. Respective transgenic plants exhibit at least one yield gain phenotype when compared to a non-transgenic plant. The present invention further relates to a method for producing a transgenic plant or part thereof, comprising introducing the transgenic expression construct of the invention into said plant or part thereof, and respective transgenic plants or parts thereof as produced.

Abstract: The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO2. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2.

Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. One of ordinary skill in the art, having this data, can obtain cloned DNA fragments, synthetic DNA fragments or polypeptides constituting desired sequences by recombinant methodology known in the art or described herein.

Abstract: Methods and materials for modulating aluminum tolerance in plants are disclosed. For example, nucleic acids encoding aluminum tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased tolerance to aluminum and methods of increasing plant yield in soil containing elevated levels of aluminum.

Abstract: Methods and materials for modulating aluminum tolerance in plants are disclosed. For example, nucleic acids encoding aluminum tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased tolerance to aluminum and methods of increasing plant yield in soil containing elevated levels of aluminum.

Abstract: This invention relates to an artificial salt tolerant protein NLEA with the amino acid sequence shown in SEQ ID No.1 and a synthetic method of salt tolerant protein NLEA comprising the steps of retrieving different types of LEA proteins from LEA database; making multiple sequence alignment on different types of LEA proteins to obtain conserved short peptides; selecting hydrophilic short peptides with a hydrophilicity index higher than 3.5 from conserved short peptides; arranging and splicing hydrophilic short peptides in the order of isoelectric point size from large to small, to obtain salt tolerant protein NLEA. This invention involves bioinformatics analysis by retrieving different LEA conserved amino acid sequences of LEA protein data. Physical properties are analyzed to find short peptides of high hydrophilicity, and such short peptides are arranged in the order of isoelectric point size and spliced to get a new hydrophilic amino acid sequence.

Abstract: The present invention relates to a genetic determinant which may comprise at least two copies of a combination of two closely linked RDR1 genes, which two closely linked RDR1 genes are inversely oriented, and which genetic determinant leads to virus resistance when present in a plant. In one embodiment, of the RDR1 genes in the combination is represented by SEQ ID No. 1 or has at least 70% sequence identity, and one of the RDR1 genes in the combination is represented by SEQ ID No. 3 or has at least 70% sequence identity; or one of the RDR1 genes in the combination encodes a protein represented by SEQ ID No. 2 or a protein that has at least 70% sequence identity, and one of the RDR1 genes encodes a protein represented by SEQ ID No. 4 or a protein that has at least 70% sequence identity.

Abstract: This disclosed subject matter concerns nucleic acid molecules and methods of use thereof for control of coleopteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in coleopteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of coleopteran pests, and the plant cells and plants obtained thereby.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.

Abstract: Methods and materials for conferring pest resistance to plants are provided. Plants are transformed with a silencing construct homologous to a gene of a plant pest that is essential for the survival, development, or pathogenicity of the pest. This results in the plant producing RNAi to the selected gene, which, when ingested by the pest results in silencing of the gene and a subsequent reduction of the pest's ability to harm the plant. In other embodiments, the pest's reduced ability to harm the plant is passed on to pest progeny. Methods and materials for depathogenesis of pests is also provided.

Abstract: Methods and compositions for a genetic disease are provided.

Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.

Abstract: The invention is directed to a system comprising a lentivirus vector particle which encodes at least one guide RNA sequence that is complementary to a first DNA sequence in a host cell genome, a Cas9 protein, and optionally a donor nucleic acid molecule comprising a second DNA sequence. The invention also is directed to a method of altering a DNA sequence in a host cell using such a system, where the host cell can be in a human and the altered DNA can be of the human ?-globin gene. The invention also is directed to a fusion protein comprising a Cas9 protein and a cyclophilin A (CypA) protein. The invention also is directed to sequences of vectors that can be used in the system and method.

Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.

Abstract: A therapeutic serum suitable for inclusion in a cosmetic preparation may be produced by stressing a co-culture including proliferative cells. The co-culture of cells may be obtained by growing first culture to less than one-hundred percent confluence on a surface. After a monolayer of first culture is established, a second culture may be seeded onto at least one cell free area on the surface, the resulting co-culture grown to less than one-hundred percent confluence. Additional cultures may then be seeded onto cell free areas of the surface and established until a monolayer having the desired population of cells is obtained. The monolayer is then stressed to obtain a serum by conditioning a collection medium. The obtained serum may be combined with a suitable cosmetic base to provide a cosmetic preparation.

Abstract: This invention generally relates to natural gas and methylotrophic energy generation, bio-generated fuels and microbiology. In alternative embodiments, the invention provides nutrient amendments and microbial compositions, e.g., consortia, that are both specifically optimized to stimulate methanogenesis, or for “methylotrophic” or other conversions. In alternative embodiments, the invention provides methods to develop nutrient amendments and microbial compositions that are both specifically optimized to stimulate methanogenesis in a given reservoir. The invention also provides methods for the evaluation of potentially damaging biomass formation and scale precipitation resulting from the addition of nutrient amendments. In other embodiments, the invention provides methods for simulating biogas in sub-surface conditions using a computational model.

Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.

Abstract: A method of producing ?-hydromuconic acid using a metabolic pathway of a microorganism is disclosed. The method of producing ?-hydromuconic acid includes the step of culturing at least one type of microorganism having a capacity to produce ?-hydromuconic acid, selected from the group consisting of microorganisms belonging to the genus Escherichia, microorganisms belonging to the genus Pseudomonas, microorganisms belonging to the genus Hafnia, microorganisms belonging to the genus Bacillus, microorganisms belonging to the genus Cupriavidus, microorganisms belonging to the genus Acinetobacter, microorganisms belonging to the genus Alcaligenes, microorganisms belonging to the genus Delftia, and microorganisms belonging to the genus Shimwellia.

Abstract: The present invention relates to a recombinant microorganism useful for the production of L-methionine and process for the preparation of L-methionine. The microorganism of the invention is modified in a way that the L-methionine production is improved by using a thiocarboxylated protein as sulfur donor and by expressing an enzyme having homoserine O-acetyltransferase activity without feedback inhibition by methionine and/or S-adenosylmethionine and an enzyme having O-acetylhomoserine sulfhydrylase activity.

Abstract: Provided herein are methods for processing biomass materials that are disposed in one or more structures or carriers, e.g., a bag, a shell, a net, a membrane, a mesh or any combination of these. Containing the material in this manner allows it to be readily added or removed at any point and in any sequence during processing.

Abstract: The present invention is directed to methods and compositions for adding tails of specific lengths to a substrate poly—nucleotide. The invention also contemplates methods and compositions for immobilization of tailed substrates to a solid support. The disclosure contemplates that the attenuator molecule is any biomolecule that associates with a tail sequence added to a substrate polynucleotide and controls the addition of a tail sequence to the 3? end of the substrate polynucleotide. The sequence that is added to the substrate polynucleotide is referred to herein as a tail sequence, or simply a tail, and the process of adding a nucleotide to a substrate polynucleotide is referred to herein as tailing.

Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.